CN100509773C - α-氨基-N-羟基-乙酰胺衍生物 - Google Patents

α-氨基-N-羟基-乙酰胺衍生物 Download PDF

Info

Publication number
CN100509773C
CN100509773C CNB028047133A CN02804713A CN100509773C CN 100509773 C CN100509773 C CN 100509773C CN B028047133 A CNB028047133 A CN B028047133A CN 02804713 A CN02804713 A CN 02804713A CN 100509773 C CN100509773 C CN 100509773C
Authority
CN
China
Prior art keywords
compound
formula
amino
salt
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028047133A
Other languages
English (en)
Chinese (zh)
Other versions
CN1525956A (zh
Inventor
早川见次
岩崎源司
小泉申一
梅村一郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1525956A publication Critical patent/CN1525956A/zh
Application granted granted Critical
Publication of CN100509773C publication Critical patent/CN100509773C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CNB028047133A 2001-02-09 2002-02-08 α-氨基-N-羟基-乙酰胺衍生物 Expired - Fee Related CN100509773C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103303.4A GB0103303D0 (en) 2001-02-09 2001-02-09 Organic compounds
GB0103303.4 2001-02-09

Publications (2)

Publication Number Publication Date
CN1525956A CN1525956A (zh) 2004-09-01
CN100509773C true CN100509773C (zh) 2009-07-08

Family

ID=9908475

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028047133A Expired - Fee Related CN100509773C (zh) 2001-02-09 2002-02-08 α-氨基-N-羟基-乙酰胺衍生物

Country Status (10)

Country Link
US (3) US7112611B2 (https=)
EP (1) EP1360175A1 (https=)
JP (1) JP4262982B2 (https=)
CN (1) CN100509773C (https=)
AR (1) AR032553A1 (https=)
AU (1) AU2002249197A1 (https=)
CA (1) CA2435611C (https=)
GB (1) GB0103303D0 (https=)
PE (1) PE20020845A1 (https=)
WO (1) WO2002064552A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) * 2001-02-09 2001-03-28 Novartis Ag Organic compounds
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
BRPI0709677A2 (pt) * 2006-03-29 2011-07-19 Novartis Ag inibidores seletivos das mmp à base de hidroxamato
US20100234378A1 (en) * 2006-08-22 2010-09-16 Array Biopharma Inc. Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors
WO2008147764A1 (en) * 2007-05-23 2008-12-04 Array Biopharma, Inc. Mmp inhibitors and methods of use thereof
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
CN110740764B (zh) * 2017-06-13 2022-05-27 爱惜康有限责任公司 具有广谱mmp抑制剂的外科紧固件
US20180353174A1 (en) * 2017-06-13 2018-12-13 Ethicon Llc Surgical Stapler with Controlled Healing
US10939911B2 (en) 2017-06-13 2021-03-09 Ethicon Llc Surgical stapler with end effector coating
US11058804B2 (en) 2017-06-13 2021-07-13 Ethicon Llc Surgical fastener device for the prevention of ECM degradation
JP7143334B2 (ja) * 2017-06-13 2022-09-28 エシコン エルエルシー 治癒を制御させる手術用ステープラ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1214041A (zh) * 1996-01-23 1999-04-14 盐野义制药株式会社 磺化的氨基酸衍生物及含有它的金属蛋白酶抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2513826A (en) 1946-12-05 1950-07-04 Gen Aniline & Film Corp Aromatic sulfonhydrazides
US4772733A (en) 1986-07-17 1988-09-20 Hercules Incorporated Epoxy-azides
US4806528A (en) 1987-09-04 1989-02-21 Hanreich Reinhard G Process for the preparation of 2-(2-chloroethoxy)-benzenesulfonamide
US5338755A (en) 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2682498A1 (fr) 1991-10-15 1993-04-16 Kodak Pathe Colorants comprenant des macrocycles thioethers.
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9503749D0 (en) 1995-02-24 1995-04-12 British Biotech Pharm Synthesis of hydroxamic acid derivatives
CA2242416C (en) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
NZ332711A (en) 1996-05-17 2000-06-23 Warner Lambert Co Biphenylsulfonylamino carboxylic acid derivatives as matrix metalloproteinase inhibitors
EP0915086A4 (en) 1996-05-24 2001-01-17 Ono Pharmaceutical Co PHENYLSULFONAMIDE DERIVATIVES
US6541276B2 (en) 1996-10-28 2003-04-01 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives and combinatorial libraries thereof
CA2263886A1 (en) 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
EP0977733B1 (en) 1997-02-03 2003-09-03 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
GB9708133D0 (en) 1997-04-22 1997-06-11 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
DE59802394D1 (de) * 1997-05-09 2002-01-24 Hoechst Ag Substituierte Diaminocarbonsäuren
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
KR100352316B1 (ko) 1997-07-31 2002-09-12 더 프록터 앤드 갬블 캄파니 메탈로프로테아제억제제로서사용되는술포닐아미노치환히드록삼산유도체
IL127496A0 (en) 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
RU2208609C2 (ru) 1998-02-04 2003-07-20 Новартис Аг Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы
JPH11236369A (ja) 1998-02-23 1999-08-31 Kotobuki Seiyaku Kk スルホンアミド誘導体及びその製造法並びにこれを含有する医薬組成物
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
WO2000037436A1 (en) 1998-12-22 2000-06-29 F. Hoffmann-La Roche Ag Sulfonamide hydroxamates
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
AR035311A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) * 2001-02-09 2001-03-28 Novartis Ag Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1214041A (zh) * 1996-01-23 1999-04-14 盐野义制药株式会社 磺化的氨基酸衍生物及含有它的金属蛋白酶抑制剂

Also Published As

Publication number Publication date
US7112611B2 (en) 2006-09-26
WO2002064552A1 (en) 2002-08-22
US20080176916A1 (en) 2008-07-24
CA2435611A1 (en) 2002-08-22
GB0103303D0 (en) 2001-03-28
AU2002249197A1 (en) 2002-08-28
CN1525956A (zh) 2004-09-01
JP4262982B2 (ja) 2009-05-13
EP1360175A1 (en) 2003-11-12
US20040082630A1 (en) 2004-04-29
JP2004523545A (ja) 2004-08-05
US7291634B2 (en) 2007-11-06
WO2002064552A8 (en) 2002-12-12
CA2435611C (en) 2011-07-12
US20060270719A1 (en) 2006-11-30
US7659293B2 (en) 2010-02-09
PE20020845A1 (es) 2002-10-30
AR032553A1 (es) 2003-11-12

Similar Documents

Publication Publication Date Title
US7659293B2 (en) α-Amino-N-hydroxy-acetamide derivatives
US8557852B2 (en) Methods of using crystalline forms of a salt of a factor Xa inhibitor
CN100553631C (zh) 4-氟-n-(1,2-二氢化茚-2-基)苯甲酰胺的制药用途
JP2013121919A (ja) 血漿カリクレイン阻害剤
EA016494B1 (ru) (2R,4αS,10αR)-4α-БЕНЗИЛ-7-((2-МЕТИЛПИРИДИН-3-ИЛ)КАРБАМОИЛ)-2-(ТРИФТОРМЕТИЛ)-1,2,3,4,4α,9,10,10α-ОКТАГИДРОФЕНАНТРЕН-2-ИЛДИГИДРОФОСФАТ ИЛИ ЕГО СОЛЬ
JP2009242437A (ja) スルホンアミド誘導体
JP2010248205A (ja) 強皮症の治療のためのベンザゾール誘導体
JP2010150275A (ja) ピラジノントロンビン阻害剤
JP2004529088A (ja) ＩｋＢキナーゼ（ＩＫＫ）のインヒビターを用いる炎症性および免疫疾患の処置法
WO2022108980A1 (en) Protein and lipid therapeutic targets
CA2860413C (en) Therapeutic use of imidazopyridine derivatives
JPH04316561A (ja) 新規イミダゾール化合物
JP2001524522A (ja) トロンビン阻害剤
US20250257061A1 (en) Compositions and methods for treating cancer and reducing wnt mediated effects
TW200400187A (en) Peptidic thrombin inhibitor compound
CN117940166A (zh) 用于治疗疼痛的sos1抑制剂和ras抑制剂
JPH0449230A (ja) トロンボキサンＡ↓ｚ拮抗剤
JPS6360739B2 (https=)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090708

Termination date: 20150208

EXPY Termination of patent right or utility model